DGX

From a fundamental perspective, Quest Diagnostics exhibits robust growth metrics. The company reported an impressive EPS of $9.05, with a quarter-over-quarter EPS growth of 15.5%. Revenue growth is even more striking, at 9.2% QoQ and an extraordinary 1178.1% year-over-year. Despite these growth figures, the stock trades at a P/E ratio of 21.6 and a forward P/E of 18.1, which suggests that while the stock is reasonably valued given its growth trajectory, it may not be significantly undervalued. Analysts are generally optimistic, with a consensus rating of BUY, comprising 2 strong buys, 7 buys, and 9 holds, and a target price of $223.44, representing a potential upside of approximately 15.3% from the current price.

Looking ahead, Quest Diagnostics is scheduled to report its next earnings on July 23, 2026, which is within the next 30 days. Investors should closely monitor this earnings report for any signs of margin compression or revenue deceleration, especially given the backdrop of significant revenue growth in the past year. Recent news, such as the company’s success in an appeal regarding 401(k) fund options and studies on antibiotic resistance, may also influence sentiment. As the earnings date approaches, key metrics to watch will include any updates on operational performance and market conditions that could affect future growth.